A general strategy for generating intact, full-length IgG antibodies that penetrate into the cytosol of living cells

Dong-Ki Choi\textsuperscript{ac}, Jeomil Bae\textsuperscript{ac}, Seung-Min Shin\textsuperscript{ac}, Ju-Yeon Shin\textsuperscript{a}, Sunghoon Kim\textsuperscript{b} & Yong-Sung Kim\textsuperscript{a}

\textsuperscript{a} Department of Molecular Science and Technology; Ajou University; Suwon, Korea
\textsuperscript{b} Medicinal Bioconvergence Research Center and Research Institute of Pharmaceutical Sciences; College of Pharmacy, Seoul National University, Seoul, Korea
\textsuperscript{c} These authors contributed equally to this work.

Accepted author version posted online: 01 Nov 2014. Published online: 15 Dec 2014.

To cite this article: Dong-Ki Choi, Jeomil Bae, Seung-Min Shin, Ju-Yeon Shin, Sunghoon Kim & Yong-Sung Kim (2014) A general strategy for generating intact, full-length IgG antibodies that penetrate into the cytosol of living cells, mAbs, 6:6, 1402-1414, DOI: 10.4161/mabs.36389

To link to this article: http://dx.doi.org/10.4161/mabs.36389
A general strategy for generating intact, full-length IgG antibodies that penetrate into the cytosol of living cells

Dong-Ki Choi¹,¹, Jeomil Bae¹,¹, Seung-Min Shin¹,¹, Ju-Yeon Shin¹, Sunghoon Kim², and Yong-Sung Kim¹,*

¹Department of Molecular Science and Technology; Ajou University; Suwon, Korea; ²Medicinal Bioconvergence Research Center and Research Institute of Pharmaceutical Sciences; College of Pharmacy; Seoul National University; Seoul, Korea

These authors contributed equally to this work.

Keywords: cell-penetrating antibody, cytosolic protein targeting, cellular internalization, endosomal release, IgG antibody, intracellular trafficking, next-generation antibody

Abbreviations: IgG, immunoglobulin G; VL, light chain variable domain; VH, heavy chain variable domain; LC, light chain; HC, heavy chain; CDR, complementarity-determining region.

Full-length IgG antibodies cannot cross cell membranes of living cells; this limits their use for direct targeting of cytosolic proteins. Here, we describe a general strategy for the generation of intact, full-length IgG antibodies, herein called cytotransmabs, which internalize into living cells and localize in the cytosol. We first generated a humanized light chain variable domain (VL) that could penetrate into the cytosol of living cells and was engineered for association with various subtypes of human heavy chain variable domains (VHs). When light chains with humanized VL were co-expressed with 3 heavy chains (HCs), including 2 HCs of the clinically approved adalimumab (Humira) and bevacizumab (Avastin), all 3 purified IgG antibodies were internalized into the cytoplasm of living cells. Cytotransmabs primarily internalized into living cells by the clathrin-mediated endocytic pathway through interactions with heparin sulfate proteoglycan that was expressed on the cell surface. The cytotransmabs escaped into the cytosol from early endosomes without being further transported into other cellular compartments, like the lysosomes, endoplasmic reticulum, Golgi apparatus, and nucleus. Furthermore, we generated a cytotransmab that co-localized with the targeted cytosolic protein when it was incubated with living cells, demonstrating that the cytotransmab can directly target cytosolic proteins. Internalized cytotransmabs did not show any noticeable cytotoxicity and remained in the cytosol for more than 6 h before being degraded by proteosomes. These results suggest that cytotransmabs, which efficiently enter living cells and reach the cytosolic space, will find widespread uses as research, diagnostic, and therapeutic agents.

Introduction

Full-length immunoglobulin G (IgG) antibodies that specifically bind to a target molecule with high affinity have been extensively developed as research tools, as well as for diagnostic and therapeutic purposes. However, their targets are primarily the proteins expressed on the cell-surface and some secreted proteins because antibodies normally cannot cross intact cellular or subcellular membranes in living cells due to their large size and hydrophilicity.¹,² In this context, stepwise cellular fixation and permeabilization are necessary to make research antibodies to recognize intracellular targeted proteins. Furthermore, disease-associated protein–protein interactions occur mainly in the cytosol of cells, and the inhibition of these interactions can be more efficiently achieved by antibodies than by small chemical agents because of the large or flat interaction surfaces of antibodies.³ Therefore, there is an increasing demand for efficient methods of antibody delivery into the cytosol of living cells for use in a diverse array of applications.⁷

Many attempts have been made to directly deliver antibodies into intracellular compartments; some of the methods used include microinjection, electroporation, and protein transfection (profection).²,⁴,⁵ Although these methods are successful for delivering antibodies into the cytoplasm of cultured living cells, many issues, including cytotoxicity, loss of antibody stability, and difficulty of systemic administration, remain unresolved.¹,² Other approaches include using targeted receptor-mediated endocytosis and genetic or chemical conjugation with protein transduction domains that directly penetrate into living cells.⁵,⁶ However, large molecules, including antibodies that enter epithelial cells via receptor-mediated endocytosis, are usually retained in endosomes and are then recycled out of the cells or are degraded in
lysosomes without being released into the cytosol.\textsuperscript{12,7} Conjugation with protein transduction domains, which are represented by cell-penetrating peptides (CPPs) such as the HIV-1 TAT peptide, has been extensively attempted in order to facilitate the intracellular delivery of antibodies formatted as single chain variable fragments (scFvs), antigen-binding fragments (Fabs), and full-length IgGs.\textsuperscript{8-10} However, most of the CPP-conjugated antibodies inherited the intrinsic intracellular trafficking of the parent CPPs, which were either entrapped inside endocytic vesicles, translocated into the nucleus, or eventually degraded in lysosomes without efficient endosomal release into the cytosol.\textsuperscript{1,10,11}

Some anti-DNA polyclonal antibodies or monoclonal antibodies (mAbs) predominantly found in humans and mice with autoimmune diseases have been shown to possess the ability to penetrate into living cells in their IgG format.\textsuperscript{12,13} Most cell-penetrating anti-DNA antibodies in the IgG or scFv formats eventually localized in cell nucleus.\textsuperscript{12,13} Taking advantage of its ability to penetrate cells and localize inside the nucleus, the murine anti-DNA SE10 scFv has been exploited for use as one arm of the bispecific antibody in the scFv-scFv format to target MDM2 protein in the nucleus.\textsuperscript{14} We previously reported the murine anti-DNA m3D8 scFv, which, unlike other anti-DNA antibodies, internalized into living cells and was localized in the cytosolic regions without further trafficking into other subcellular compartments, including the nucleus.\textsuperscript{15} The ability of m3D8 scFv to penetrate cells and then localize into the cytosol (referred to herein as ‘cytosol-penetrating ability’) was derived from the m3D8 VL.\textsuperscript{16,17} Thus, m3D8 VL is an ideal moiety for the generation of cytosol-penetrating antibodies that can be used for diverse purposes.

In this study, we aimed to generate a cytosol-penetrating antibody, which we called ‘cytotransmab’, in the form of a full-length IgG by incorporating a cytosol-penetrating VL into light chains (LCs) and then co-expressing the LCs with the heavy chains (HCs). For this, we first generated humanized VLs that retained the cytosol-penetrating ability of m3D8 VL and contained the consensus residues at the interface with the heavy chain variable domain (VH) for proper association with the VH partner. When the LCs containing the humanized VL were co-expressed with the HCs carrying various subtypes of VHs, the purified IgG mAbs internalized into living cells through a physiological endocytic pathway and then reached the cytosol regions. Furthermore, we show that our strategy facilitates the generation of a cytotransmab that can directly target cytoplasmic proteins when it is incubated with living cells under normal culture conditions.

**Results**

**Generation of a cytosol-penetrating antibody containing humanized VL single domain**

We previously generated a humanized VL, named hT0, by grafting the complementarity-determining regions (CDRs) of the m3D8 VL (first found in mice) into the corresponding regions of a human framework region of Vk3 and Jk1 gene segments.\textsuperscript{18} However, in live HeLa cells (human cervix carcinoma), hT0 failed to bind to cell surfaces, leading to complete loss of the cell-penetrating ability of m3D8 VL.\textsuperscript{16,17} (Fig. 1A). The cell-penetrating ability of m3D8 VL was conferred by VL-CDR1 with a unique cationic patch that is composed of Arg27f, Arg29, and Lys30.\textsuperscript{16} Superimposition of the model of the homologous hT0 structure using the WAM algorithm\textsuperscript{19} and the reported crystal structure of m3D8 VL\textsuperscript{20} revealed that the regions from Phe27c to Lys30 of hT0-CDR1 have deviated from their positions on m3D8 VL; an approximately 5.3 Å shift was revealed between the 2 Cα atoms of Arg27f at the tip of the loop, while the other CDRs were largely well superimposed on each other (Fig. 1B). Some residues in the β-sheet framework regions that closely underlie CDRs, called Vernier-zone residues, play a critical role in adjustment of the loop structures of CDRs, thus affecting CDR loop conformation.\textsuperscript{21} Of the 14 amino acid residues that were determined to be Vernier-zone residues,\textsuperscript{21,22} only 2, the Ile2 and Leu4 residues of hT0 (which were positioned right below CDR1), were different from Leu2 and Met4 residues of m3D8 (Fig. S1A). Back mutations of these 2 residues with the corresponding murine residues (I2L and L4M) in hT0 predicted a similar CDR1 conformation to that of m3D8-CDR1 (Fig. 1B). Thus, we generated an hT0 variant, named hT2, with I2L
and L4M substitutions (Fig. S1A). Similar to m3D8 VL, the soluble, purified hT2 VL internalized into cytoplasmic regions of HeLa cells without further trafficking into the nucleus (Fig. 1A), indicating that the CDR1 conformation, rather than the linear amino acid sequence, is a determining factor for cell-penetrating activity.

Most commercialized therapeutic mAbs have a Vk1 subgroup of the VL gene family rather than Vk3 subgroup for pairing with various VH subgroups. Accordingly, we generated an hT3 VL, which had the same consensus framework sequence of the human Vk1 and Jk1 genes and the same CDR sequences as hT2 VL (Fig. 1A and S1A). Soluble, purified hT3 VL also internalized and dominantly accumulated in the cytoplasmic regions of HeLa cells (Fig. 1A). Investigation of cellular internalization mechanisms revealed that the humanized hT2 and hT3 VLs retained the caveolae-mediated endocytosis pathway of m3D8 VL rather than by clathrin-mediated endocytosis or macropinocytosis (Fig. S1B and S1C).

Figure 2. Generation of cytosol-penetrating intact IgG-format cytotransmabs, which internalize into living cells and then localize in the cytosol without cytotoxicity. (A) Schematic diagram showing the general strategy for generation of cytotransmabs by replacing endogenous VL of conventional IgG with the humanized cytosol-penetrating hT4 VL. (B and C) Biochemical characterizations of the purified parent mAbs and cytotransmabs by reducing and non-reducing SDS-PAGE (B) and SEC (C) analyses. In (B), the purified antibodies (5 μg) were separated on 12% SDS polyacrylamide gels and visualized by Coomassie brilliant blue staining (R-250). In (C), the purified antibodies were injected at 200 μg/mL in 70 μL of sample volume and monitored at 280 nm. Arrows indicate the elution positions of molecular weight standards. (D) Cellular internalization and localization of cytotransmabs (TMab4, HuT4, and AvaT4) and control mAbs (adalimumab and bevacizumab) in HeLa cells that were treated with the antibodies (1 μM) for 6 h at 37°C and then analyzed by confocal immunofluorescence microscopy. (E) Concentration-dependent internalization of TMab4 in HeLa cells that were treated with TMab4 (1 μM) at 37°C for the indicated periods. In (D–F), after removing cell-surface bound antibodies with low pH glycine buffer (pH 2.5), internalized antibodies were visualized with FITC-conjugated anti-human IgG Fc antibody (green). Images show the merging of antibodies (green) and Hoechst33342-stained nuclei (blue) at the centered single confocal section. Image magnification, 630×; scale bar, 10 μm. (G and H) Cytotoxicity of internalized cytotransmabs in HeLa cells that were treated with the antibodies (1 μM) at 37°C for 24 h or 48 h. In (G), the morphological features of cells were observed by phase-contrast microscopy after 48 h. Image magnification, 200×; scale bar, 10 μm. In (H), the cell viability was determined by MTT assay after 24 h or 48 h. The data represent mean ± SD compared with the PBS-treated controls.
Design of cytotransmabs by incorporation of humanized, cytosol-penetrating VL

We sought to develop a general strategy for the generation of cytosol-penetrating IgG-format cytotransmabs by replacing the VL in conventional IgG1 format with the humanized cytosol-penetrating VL (Fig. 2A). As an HC partner, we chose IgG1-isotype HC with humanized h3D8 VH, generated by grafting the 3 CDRs of m3D8 VH into the corresponding regions of human framework with VH3–23 (DP-47), JH6, and DH3 gene segments.18 To test the general applicability of this strategy, we further chose 2 HCs from clinically approved mAbs: adalimumab (Humira®) against tumor necrosis factor (TNF)24 and bevacizumab (Avastin®) against vascular endothelial growth factor A (VEGF).25 Adalimumab (IgG1 with VH3-VK1) and bevacizumab (IgG1 with VH7-VK1) were selected because they could not internalize into cells since they bind to the secreted cytokines, but not to any cell surface-expressed receptors. Furthermore, they have the most predominant VH-VL subtype pairing among the clinically approved mAbs with the same VK1 subtype as hT3.23

To evaluate whether hT3 (VK1) can be properly associated with the chosen VHs for IgG-format expression, we first analyzed the VH-interacting residues of hT3 VL (Fig. S2). Previous structural analyses of 23 crystallized VH-VL interfaces identified 10 positions of VL that were primarily involved in VH interactions, with the highest contact frequencies within a 4.1 Å distance from the corresponding VH residue atoms.26 hT3 VL had amino acid residues observed most frequently at all of the VH-interacting positions, except for 2 residues of K89 and S91 in VL-CDR3 that commonly interact with 103–3 and 95 residues in VH-CDR3, respectively (Fig. S2A).27,28 Improper association between VH and VL could impair the assembly between HCs and LCs in the IgG-format antibodies, leading to a decrease in the expression, stability, or antigen binding.27 Indeed, co-expression of LC carrying hT3 VL with the chosen HCs to generate IgG-format antibodies resulted in decreased IgG production yield compared with the parent mAbs (Table 1). Hence, we designed an hT3 variant, named hT4, with 2 substitutions of K89Q and S91Y to have the most frequently observed amino acid residues at the 2 positions such that hT4 can be broadly associated with various human VH gene family members (Fig. S2B).

Generation of cytosol-penetrating cytotransmabs

Both plasmids that encode HCs, which were composed of the chosen VH-IgG1 HC constant domains (CH1-hinge-CH2-CH3) and LCs of the hT4 VL-Ck constant domain, were transiently co-transfected into HEK293F cells to express the IgG1-format cytotransmab, generating TMab4 (h3D8 HC-hT4 LC), HuT4 (Humira HC-hT4 LC), and AvaT4 (Avastin HC-hT4 LC) (Table 1). All of the cytotransmabs were well expressed in correctly assembled form and showed production yields (~8–10 mg/L of culture) comparable to those of the parent mAbs (Fig. 2B and Table 1). The purified cytotransmabs existed in the intact monomeric form without soluble oligomers as assessed by size-exclusion chromatography (SEC) analyses (Fig. 2C). Because of the replacement of the original VLs with hT4 VL, HuT4 and AvaT4 lost their associated antigen binding activity (Fig. S3A). None of the cytotransmabs showed any nuclease activity (Fig. S3B).

When the 3 cytotransmabs were incubated at 37°C for 6 h with live HeLa cells under normal culture conditions in a medium with 10% fetal bovine serum (FBS), they internalized into the cytoplasmic regions of cells with little accumulation in the nucleus (Fig. 2D). Internalized cytotransmabs were seen as diffuse fluorescence throughout the cytosol and intense punctate fluorescence within the cytoplasm, indicating that some of them reached the cytosol and others remained entrapped within endocytic vesicles. As expected, the parent adalimumab and bevacizumab mAbs failed to internalize into the cells (Fig. 2D). The cytotransmabs also efficiently penetrated into other human cell lines, including PANC-1 (pancreatic carcinoma), HT-29 (colorectal carcinoma), and MCF-7 (breast carcinoma) cells, showing similar diffusive and punctate distributions in the cytoplasmic regions compared to those of HeLa cells (Fig. S4A).

Table 1. Purification yields of modeled mAbs and cytotransmabs that were obtained by transient expression in HEK293F cells

| IgG clones     | VH of HCa | VL of LCa | IgG purification yield (mg/1 L of transfected cells)b,c |
|----------------|-----------|-----------|---------------------------------------------------------|
| TMab3          | h3D8      | hT3       | 8.2 ± 0.5                                               |
| TMab4          | h3D8      | hT4       | 10.8 ± 1.0                                              |
| Adalimumab     | Adalimumab| hT3       | 3.5 ± 0.8                                               |
| HuT3           | Adalimumab| hT4       | 10.9 ± 0.8                                              |
| HuT4           | Adalimumab| hT3       | 8.8 ± 0.4                                               |
| Bevacizumab    | Bevacizumab| hT4      | 4.5 ± 0.8                                               |
| AvaT3          | Bevacizumab| hT3      | 22.5 ± 2.5                                              |
| AvaT4          | Bevacizumab| hT4      | 21.3 ± 0.9                                              |
| C20            | C20       | C20       |                                                        |
| KT4            | C20       | hT4       |                                                        |

a The constant domains of HC and LC were the IgG1-isotype and Ck, respectively.
b The 2 plasmids that encode the HC and LC of each IgG antibody were co-transfected with the equivalent molar ratio into HEK293F cells in 1 L of culture media following standard protocol.29

c After 7 d of culture, antibodies were purified from the cell culture supernatant using a protein-A affinity column. The values represent mean ± SD of at least 3 independent experiments.
internalized cytotransmabs were detected in all of the cells as revealed by confocal fluorescence microscopy (Fig. S4B), indicating that the internalization efficiency almost reached 100%. The internalizing efficiency of cytotransmabs was further confirmed by flow cytometric analysis (Fig. S4C).

Cellular internalization of TMab4 was readily detected above 100 nM and increased in proportion to concentration increase (Fig. 2E), indicating that the internalizing activity of cytotransmab is improved by $\sim$100-fold compared with that of hT3 VL (Fig. 1A). Time-course analyses revealed that TMab4 internalization was significantly detected as early as 30 min, gradually increased with incubation time with plateaued levels between 2 h and 12 h, and subsequently decreased at 24 h with almost disappearance after 48 h (Fig. 2F). Noticeably, internalization of TMab4, HuT4, and AvaT4 cytotransmabs did not cause any noticeable cytotoxicity when tested in HeLa and PANC-1 cells for either 24 h or 48 h of incubation (Fig. 2G and H; Fig. S5).

**Endocytic mechanisms underlying cytotransmab internalization**

To elucidate the internalization mechanism(s) of cytotransmabs, we first tested their temperature dependence. Cellular internalization of TMab4 into HeLa cells at 37°C was totally blocked at 4°C (Fig. 3A), which indicates that the internalization occurs through an energy-dependent, endocytic pathway.29 We previously reported that cellular uptake of m3D8

![Figure 3](image-url)

**Figure 3.** Cytotransmabs internalize into living cells primarily by energy-dependent, clathrin-mediated endocytosis through interactions with cell-surface HSPG. (A) Effect of temperature on the internalization of cytotransmabs into HeLa cells that were incubated with TMab4 or HuT4 (1 μM) for 6 h at 4°C or 37°C. (B) Effect of an external heparin competitor on cytotransmab internalization into HeLa cells that were treated with heparin (300 IU/mL) for 30 min at 37°C before incubating TMab4 or HuT4 (1 μM) for an additional 6 h. (C) Internalization of cytotransmabs into CHO-K1 wild type and pgsD-677 mutant (HSPG-deficient) cells that were incubated with TMab4 or HuT4 (1 μM) for 6 h at 37°C. (D) Internalization of cytotransmabs into non-adherent K562 (HSPG-expressed) and Ramos (HSPG-deficient) cells that were treated with TMab4 (1 μM) for 6 h at 37°C. In (A–D), internalized cytotransmabs were observed by confocal microscopy after staining with FITC-conjugated anti-human IgG Fc antibody (green) and nuclei with Hoechst33342 (blue). (E) Co-localization of internalized cytotoxtransmabs with endocytosis markers. HeLa cells were co-incubated with cytotoxtransmabs (1 μM) and endocytosis markers including 10 μg/mL of Alexa Fluor 488-transferrin (TF, green), FITC-cholera toxin B (Ctx-B, green), and Oregon green-dextran (Dextran, green) for 30 min at 37°C. Subsequently, internalized cytotoxtransmabs were stained with TRITC-conjugated anti-Human IgG Fc antibody (red). The regions in the white box were magnified for better imaging of co-localization. In (A–E), centered single confocal sections are shown. Image magnification, 630 x; scale bar, 5 μm. (F) Effect of endocytosis inhibitors on TMab4 internalization. HeLa cells were pre-treated for 30 min with the indicated endocytosis inhibitors, and then incubated with TMab4 for additional 2 h, followed by immunofluorescence staining, as shown Fig. S6. The internalization levels of TMab4 in the presence of inhibitors are represented as mean percentage (%) ± SEM by comparing the fluorescence intensity from inside of cells ($n > 100$ cells per group) with that of the untreated ‘control’. ***$p < 0.001$ compared with the control.
VL was initiated by non-specific electrostatic interactions with negatively-charged glycosaminoglycan heparan sulfate (HS), which was linked as a side chain to cell surface core proteins to form HS proteoglycan (HSPG).16,17 The presence of exogenous heparin, which is a close structural homolog of HS, significantly inhibited the cellular internalization of TMab4 and HuT4 (Fig. 3B). Additionally, TMab4 and HuT4 efficiently internalized into the cytoplasmic compartments of wild type CHO-K1 cells, but completely failed to internalize into HS-deficient pgpD-677 CHO-K1 mutant cells (Fig. 3C). In accordance with the above results with adherent cells, TMab4 entered non-adherent K562 (human erythroleukemia) cells with HSPG expression, but did not enter non-adherent Ramos (human Burkitt’s lymphoma) cells, which are deficient in cell-surface HSPGs30 (Fig. 3D). Overall, these results provide biochemical and genetic evidence that cell surface HSPGs are the primary cellular receptors for cell-surface binding prior to the internalization of cytotransmabs.

To determine the specific endocytosis pathway that functions to internalize cytotransmabs, internalized TMab4 and HuT4 were co-stained with specific endocytic markers of the 3 main endocytosis pathways, including transferrin (TF) for clathrin-mediated endocytosis, cholera toxin B (Ctx-B) for caveolae-mediated endocytosis, and dextran for macropinocytosis.7,15,31 Cytotransmabs-containing punctate vesicles mainly co-localized with TF and partly with Ctx-B, but did not localize at all with dextran (Fig. 3E). Accordingly, the cytotransmabs seemed to primarily internalize via clathrin-mediated endocytosis and partly via caveolae-mediated endocytosis. This result was further confirmed by studies with pharmacological inhibitors of this endocytosis pathway (Fig. 3F; Fig. S6). Chlorpromazine (CPZ) and dansylcadaverine (inhibitors of clathrin-mediated endocytosis) remarkably inhibited cellular uptake of TMab4. In contrast, methyl-β-cyclodextrin (MβCD) and nystatin (inhibitors of caveolae-mediated endocytosis), as well as 5-(N-ethyl-N-isopropyl) amiloride (EIPA) and Wortmannin (inhibitors of macropinocytosis), negligibly affected TMab4 internalization. Actin dynamics are required for clathrin-mediated endocytosis, and dynamin is essential for the fission of endocytic vesicles from the plasma membrane in both clathrin- and caveolae-mediated endocytosis.7 As expected, cytochalasin D (Cyt-D) (inhibitor of actin-dependent endocytosis) and dynasore (dynamin inhibitor) also modestly impaired the internalization.

**Intracellular trafficking and stability of internalized cytotransmab**

To determine intracellular trafficking routes and the stability of cytotransmabs, a pulse-chase experiment was performed. After HeLa cells were incubated with TMab4 (3 μM) for 30 min, the cells were completely washed with low pH glycine buffer to remove non-internalized, surface-bound cytotransmabs. Thereafter, time-course intracellular routes of pulsed TMab4 were tracked by co-staining with endosome/sub-organelle markers, including EEA-1 for early endosomes, LysoTracker for lysosomes, caveolin-1 for caveosomes, calnexin for endoplasmic reticulum (ER), and 58K Golgi for Golgi apparatus. Alexa Fluor 488-labeled TF, which was destined to a recycling pathway or to lysosomal degradation after clathrin-mediated endocytosis, was also traced with TMab4 to compare intracellular stability.

After 0 h of tracing (i.e., after 30 min of internalization), TMab4 was detected in a dispersive pattern throughout the cytosol, as well as in small punctate, cytoplasmic vesicular structures that were dominantly co-localized with co-treated TF and partially with caveolin-1 and EEA-1, but not with the other sub-organelle markers of LysoTracker, calnexin, and 58K Golgi (Fig. 4A). At 2 h, TMab4 was substantially detected with similar patterns to those at 0 h. However, co-treated TF totally disappeared at 2 h, which is indicative of rapid recycling back out of cells by trafficking into recycling endosomes or lysosomal degradation, which is consistent with the findings of a previous study.32 This indicates that the endocytic vesicles containing TMab4 are more sustainable in the cytoplasmic spaces than those containing TF, even though both TMab4 and TF are initially similarly internalized by clathrin-mediated endocytosis. At 6 h, TMab4 signals were significantly reduced and the remaining punctate vesicles were still partially co-localized with EEA-1 without transporting to the lysosomes, ER, and Golgi apparatus. At 18 h, TMab4 completely disappeared. These results indicate that TMab4 mainly internalizes via clathrin-mediated endocytosis, localizes in early endosomes, and is then directly released into the cytosol from the early endosomes without further trafficking into the lysosomes, ER, Golgi apparatus, and nucleus, thereby persisting in the cytosol for more than 6 h prior to degradation.

To elucidate the degradation mechanism of internalized TMab4, we examined the effects of MG132, an inhibitor to proteasomal degradation of ubiquitin-conjugated proteins,33 on the time-course intracellular stability of TMab4 after treatment for 30 min with HeLa cells. Confocal fluorescence microscopic analyses showed that the presence of MG132 made TMab4 substantially persist in the cytosol after 6 h and even slightly persist after 18 h (Fig. 4B), which was also confirmed by western blotting (Fig. 4C). Since the ubiquitin-proteasome proteolytic machinery operates in the cytosol of cells,34 the above results strongly support the cytosolic localization of TMab4 and its degradation by the cytosolic proteasomes.

Cytosolic release activity of cytotransmabs was further assessed by monitoring cytosolic release of calcine that was co-treated with cytotransmabs. Calcine, a membrane-impermeable fluorophore, was employed as a cargo tracer for cytosolic release from endosomes after endocytic uptakes by co-treated internalizing agents, because it cannot penetrate into cytosol from endosomes for itself.35 Treatment of calcine alone with live HeLa cells did not display any significant fluorescence in the cytosol while showing very dim fluorescence in the punctate endosomal pattern (Fig. 4D). However, the co-treatments of calcine with either TMab4 or HuT4, but not adalimumab, induced diffused calcine fluorescence throughout the cytoplasm of cells in addition to the punctate endosomal fluorescence (Fig. 4D), indicating that the cytotransmabs induced cytosolic release of calcine from endosomes.

We further monitored the cellular uptake and cytosolic localization of TMab4 using live-cell time-lapse fluorescence imaging for 2 h by incubating Alexa Fluor 488-labeled TMab4 with HeLa cells. Internalization of TMab4 occurred very rapidly, as
indicated by the appearance of small punctate, cytoplasmic vesicles (Fig. S7A and Movie S1), which seem to be the early endosomes (Fig. 4A). The number of cytoplasmic vesicles increased over time in the cytosolic regions without further trafficking into the nucleus (Fig. S7A and Movie S1), which is consistent with the above pulse-chase trafficking results (Fig. 4A).

Simultaneously, diffuse fluorescence signals steadily accumulated throughout the cytosolic regions (Fig. S7B), which is indicative of the direct release of TMab4 into the cytosol from early endosomes.

Cytotransmab penetrates and directly binds to a targeted cytosolic protein

To test whether cytotransmabs can directly target cytosolic proteins from outside of living cells, we generated a cytotransmab that specifically binds to human lysyl-tRNA synthetase (KRS), a cytosolic protein as a component of the multi-tRNA synthetase complex. We first generated a fully human C20 mAb, which specifically bound to KRS, primarily via the VH domain, with an apparent dissociation equilibrium constant ($K_D$) of $\sim$0.58 nM (Fig. S8). Then, the VL of C20 was replaced with hT4 VL, which generated a KRS-targeting cytotransmab that was named KT4 (Fig. 5A).

KT4 was well expressed, showing a similar purification yield to that of C20 (Table 1). KT4 specifically bound to KRS with an apparent $K_D$ of $\sim$36 nM (Fig. S8), but did not cross-react with other aminoacyl-tRNA synthetases (ARSs) (Fig. 5B). In order to determine the direct cytosolic KRS targeting ability of KT4 after cellular internalization, KT4 was incubated with HeLa cells expressing green fluorescent protein (GFP)-fused KRS. KT4, but not TMab4, successfully co-localized with KRS in the cytosolic regions (Fig. 5C). However, a substantial portion of KT4 that was detected in punctate endocytic vesicles did not co-localize with KRS, indicating that KT4, which is sequestered into early endosomes, needs to be released into the cytosol in order to recognize
the cytosolic target protein. The poor cytosolic release from early endosomes were also observed for cell-penetrating cationic proteins, which showed about 1 to 5% cytosolic access efficiency from their endocytosed vesicles. The specific interaction between KT4 and KRS in the cytosol was further confirmed by immunoprecipitation experiments for the lysates of HeLa cells that were pre-treated with KT4 for internalization prior to cell lysis. KRS co-precipitated with internalized KT4, but not internalized TMab4 (Fig. 5D).

Discussion

Innovative technology that enables full-length IgG antibodies to directly target cytosolic proteins is in high demand for a diverse array of applications, and these antibodies can be used as analytical and functional research agents in living cells, as well as imaging and therapeutic agents that target intracellular proteins. Here, we demonstrated a proof-of-concept for cytosol-penetrating IgG-format cytotransmabs that were generated by incorporation of a humanized, cytosol-penetrating VL into the VL position of conventional IgG mAbs. Simple pairing of LCs that contained the cytosol-penetrating VL with HCs transforms conventional mAbs into cytotransmabs, as evidenced by pairing with HCs of adalimumab and bevacizumab. Current approaches for intracellular delivery of antibodies, such as CPP-conjugated and anti-DNA scFv-fused antibodies, are almost restricted to nuclear targets because of the intrinsic nuclear targeting property of the carrier. On the other hand, cytotransmabs penetrated into the cytosol of living cells, enabling its direct targeting of cytosolic proteins.

We generated the humanized, cytosol-penetrating hT4 VL based on the consensus framework sequence of Vk1 family germline segments with consensus residues at the interface with VH for proper association with VH. In this study, hT4 VL was well associated with VHs that were derived from either VH3 or VH7 family germline segments showing that the assembled cytotransmabs were well expressed in correctly assembled form without any compromise in the production yield compared to the parent mAbs. It is not certain whether hT4 VL is well associated with the other VH family germline segments. However, based on the successful generation of cytosol-penetrating VLs with Vk3 (hT3) or Vk1 (hT4) subtypes, we believe that cytosol-penetrating VLs can be rationally designed according to other VH subtypes for cytotransmab generation.

Cytotransmabs did not show noticeable cytotoxicity, which is indicative of their internalization via a physiological endocytosis pathway without plasma membrane disruption. The inability of cytotransmabs to internalize into HSPG-deficient cells demonstrated that their cellular uptake initiated via HSPGs as cell surface receptors, like the parent VLs, though the precise HSPG molecule remains to be identified. HSPGs commonly serve as internalizing receptors for many macromolecules, including CPPs, anti-DNA antibodies, polycation–nucleic acid complexes, viruses, and growth factors. Notably, endocytosis that is

Figure 5. Anti-KRS KT4 internalizes into living cells and binds to the cytosolic KRS. (A) Diagram of IgG-format KT4 carrying KRS-binding C20 VH domain and cytosol-penetrating hT4 VL domain. (B) Direct ELISA to determine the binding specificity of C20 and KT4 IgG antibodies (100 nM) to plate-coated antigens (1 µg/mL), KRS, histidyl-tRNA synthetase (HRS), tryptophanyl-tRNA synthetase (WRS), or ARS-interacting multifunctional protein 1 (AIMP1). TMab4 was employed as a negative control. (C) Co-localization of internalized KT4 with KRS in GFP-fused KRS expressing HeLa cells, treated KT4 or TMab4 (20 µM) for 2 h at 37°C, and then determined by confocal microscopy. KT4 and TMab4 were visualized with TRITC-conjugated anti-Human IgG Fc antibody. Image magnification, 630×; scale bar, 5 µm. Images show the KRS (green), antibodies (red), and Hochest33342-stained nuclei (blue) at the centered single confocal section. Mide insets, enlarged images of the boxed regions. (D) Western blot analysis of immunoprecipitation (IP) of KRS by internalized KT4. The cell lysates prepared from HeLa cells that were treated with PBS (control), KT4 (6 µM), or TMab4 (6 µM) for 12 h at 37°C were precipitated using protein A agarose and analyzed by western blotting with β-actin as a loading control.
initiated by HSPG interactions does not follow one particular pathway, but instead varies depending on the cellular context and type of extracellular binding ligand. Previous studies have shown that, after binding of HSPG at the cell surface, some proteins or CPPs are internalized by clathrin-mediated endocytosis, whereas other CPPs, such as HIV1-TAT, are internalized via caveolae-mediated endocytosis. Intriguingly, cytotransmabs with the embedded cytosol-penetrating VL are primarily internalized by clathrin-mediated endocytosis, while the parent VLs retained the caveolae-mediated endocytic mechanism. Thus, HSPG acts as cell surface receptor, but does not determine the subsequent endocytic pathway. Size of clathrin-coated vesicles and caveosomes are ~200 nm and 50 nm–60 nm in diameter, respectively, both of which are large enough to contain an approximately 10 nm IgG antibody and smaller VL, indicating that the antibody size is not a determining factor. The Fcγ receptors that interact with the Fc region of IgG are exclusively expressed in immune cells, but are not normally expressed in cancer cells, excluding their involvement in the cellular uptake of cytotransmabs in cancer cells. Although neonatal Fc receptor is ubiquitously expressed in epithelial cells, endothelial cells and many other cell types, it only interacts with the Fc portion of IgG in acidic endosomal compartments, excluding their involvement as cell-surface receptors for the internalization of cytotransmabs. We speculate that bivalent engagement of HSPG by cytotransmab induces different conformations of HSPG from those induced by VL monovalent binding to preferentially recruit proteins that are involved in clathrin-mediated endocytosis compared with those that are involved in caveolae-mediated endocytosis. The bivalency of cytotransmab might also mediate more efficient cellular uptake and early endosome escape by being readily detected, even at ~100-fold lower concentrations compared with the monovalent VLs, as was seen for multivalent CPPs.

Although cargo proteins that are internalized by clathrin-mediated endocytosis often route to late endosomes and subsequently undergo lysosomal degradation (or routes to recycling endosomes), this is not always the case, as exemplified by cytosolic release of some CPPs or toxins after cellular uptake by clathrin-mediated endocytosis. Several lines of evidence, such as intracellular distribution and trafficking studies by confocal microscopy, direct access of VT4 to cytosolic KRS proteins, and calcine release assay, indicate that endocytosed cytotransmab is directly released to cytosol from early endosomes, passing over lysosome, ER, Golgi, and nucleus trafficking. However, the underlying molecular mechanism by which cytotransmab escapes from early endosomes into the cytosol is not clear. The cytotransmab carrying hT4 VL with multiple basic residues on the CDR1 might destabilize early endosomes or interfere with further maturation to late endosomes/lysosomes, and this is supported by content releases from vesicles via interactions of oligoarginines with anionic vesicles. Taking advantage of the cytosol-penetrating ability of cytotransmabs, we generated anti-KRS VT4 that directly accesses the cytosolic antigen KRS after incubation with living cells under normal cell culture conditions. VT4 is an example of a dual-specific cytotransmab that directly targets cytosolic proteins of living cells, which are generated by the combination of the KRS-binding VH domain and cytosol-penetrating VL domain into the IgG framework. Recently developed antibody engineering techniques can generate VH to specifically recognize targeted antigens with high affinity without the help or interference of VL, as evidenced by VH single domain antibodies and dual-specific antibodies. Thus, we envision that cytotransmab technology has the potential to directly target cytosolic proteins.

The intact IgG-format cytotransmab designed in this study can be produced in large-scale using conventional mAb production techniques and holds many desirable features of the conventional IgG mAbs, including the pharmacokinetic behavior and immune cells-recruiting ability. However, many issues should be first addressed for practical in vivo applications of cytotransmabs, including more efficient cellular uptake at the achievable physiological concentration after their systemic administration and more rapid and sufficient cytosolic access from the endocytosed vesicles. Although internalized cytotransmab did not show any noticeable cytotoxicity, lack of tissue specificity of cytotransmab, which is due to internalization through HSPG that is ubiquitously expressed in epithelial cells, is another issue to be addressed for the systemic applications of cytotransmabs. Nonetheless, the ability of cytotransmab to directly access cytosolic proteins after physiological endocytosis makes it an ideal candidate for construction of next-generation therapeutic antibodies that directly target cytosolic proteins that are associated with many human diseases, including tumors. Furthermore, degradation of cytosolic cytotransmabs by the ubiquitin-mediated proteasome pathways makes them suitable carriers for the cytosolic delivery of therapeutic agents such as chemical drugs and toxins. In conclusion, cytotransmab technology has the potential to generate full-length IgG-format antibodies for detection of cytosolic proteins as research and diagnostic agents, as well as inhibition of cytosolic protein-protein interactions as therapeutic agents.

Materials and Methods

Cell lines

The cell lines, human cervix carcinoma HeLa, pancreatic carcinoma Panc-1, colorectal carcinoma HT-29, breast carcinoma MCF-7, erythroleukemia K562, Burkitt’s lymphoma Ramos, Chinese hamster ovary CHO-K1, and proteoglycan-deficient CHO-K1 mutant pgsD-677, were purchased from American Type Culture Collection (ATCC). HeLa and Panc-1 cells were maintained in Dulbecco’s Modified Eagle Medium (DMEM, Welgene, LM 001–11), and HT-29, MCF-7, K562, Ramos, CHO-K1, and pgsD-677 cells were maintained in Roswell Park Memorial Institute medium (RPMI, Welgene, LM 011–01). The pgsD-677 cell line lacks both N-acetylgalcosaminyltransferase and glucuronyltransferase activities that are required for synthesis of HS, causing selective depletion of HS without affecting chondroitin sulfate (CS) production. All cells were cultured in growth media that was supplemented with 10% (v/v) heat-inactivated FBS (Welgene, S 001–07), 100 U/mL penicillin, and...
100 μg/mL streptomycin (Welgene, LS 202–02). All of the cell lines were maintained at 37°C in a humified 5% CO₂ incubator and routinely screened for *Mycoplasma* contamination (CellSafe).

**Modeling of humanized VL single domain antibodies**

Modeling of the 3-dimensional structure of humanized VLs from the primary amino acid sequence was performed using the web antibody modeling (WAM) algorithm (http://antibody.bath.ac.uk/). WAM offers an improved algorithm for homology CDR modeling of VH and VL by aligning the submitted sequence with the most similar framework regions and CDRs of the same canonical class, respectively, from the Brookhaven Protein Data Bank of known antibody structures.

**Construction, expression, and purification of humanized VL single domain antibodies**

The hT2 VL was generated by introducing 2 point mutations (I2L, L4M) into hT0 VL by overlapping PCR. The hT3 VL was constructed by grafting CDRs of hT2 VL into the human 4D5 VL framework with Vκ1–39 and Jκ1 (PDB 1fvc), which conserves the Verner zone and N-terminal D1 to M4 residues in hT2 VL. The hT4 VL was constructed by introducing 2 point mutations (K89Q, S91Y) into hT3 VL using overlapping PCR. The amino acid sequences of all VLs are shown in the supplementary data (Figs. S1A and S2A). The genes that encode the hT VL variants were cloned into the *NheI/BamHI* site of the pIg20 vector, which had a protein A tag at the C-terminus. m3D8 and hT VL variants containing the protein-A tag were purified from the supernatant of bacterial cultures using IgG-Sepharose affinity chromatography, as previously described.

**Construction of intact IgG cytotransmabs**

The VH and VL genes for anti-TNF adalimumab (PDB 3wd5) (DrugBank Accession No. DB00051) and anti-VEGF bevacizumab (PDB 1bj1) (DrugBank Accession No. DB00112) were prepared by DNA synthesis (Bioneer, Inc.) using the sequence from the published crystal structure. The VH and VL genes of TMab4 were amplified from the bacterial plasmids or prepared by DNA synthesis. The VH and VL genes were subcloned in-frame without additional amino acids into the NorI/Apal sites of the pcDNA 3.4-HC vector carrying human IgG1 constant domain sequence (CH1-hinge-CH2-CH3, residues 118–447 in EU numbering) and NorI/BsuWI sites of the pcDNA 3.4-LC vector with the Cκ constant domain sequence (residues 108–214 in EU numbering), respectively.

**Generation of anti-KRS KT4 cytotransmab**

Anti-KRS C12 scFv antibody was isolated from a synthetic human scFv phage library. Using yeast surface display technology, the C12 Fab was further engineered by randomization of VH-CDR3 to isolate a high affinity anti-KRS scFv, the binding of which was primarily mediated via the VH domain. The resulting C20 Fab with the engineered VH was formatted into IgG1 by subcloning the VH and VL genes into the plasmids of pcDNA 3.4-HC and pcDNA 3.4-LC, respectively, generating C20 IgG mAb. KT4 cytotransmab was generated by co-expression of HC of C20 mAb and LCs that were composed of hT4 VL and Cκ.

**Expression and purification of IgG antibodies**

The plasmids that encode HC and LC were transiently co-transfected in pairs at an equivalent molar ratio into 200 mL – 1 L of HEK293F cell cultures in Freestyle 293F media (Invitrogen) following a previously described standard protocol. Culture supernatants were harvested after 7 d at 37°C in a humified 8% CO₂ incubator by centrifugation and filtration (pore size 0.22 μm, cellulose acetate, Corning, CLS430521). Antibodies were purified from the culture supernatants using a protein-A agarose chromatography column (GE Healthcare) and dialyzed to achieve a final buffer composition of PBS with pH 7.4. Prior to cell treatments, antibodies were sterilized by filtration using a cellulose acetate membrane filter (pore size 0.22 μm, Corning). Antibody concentrations were determined using a Bicinchoninic Acid (BCA) Kit (Pierce, 23225).

**Cell viability assay**

Cytotoxicity of cytotransmab on tumor cells was determined as previously described. Briefly, cells were seeded at a density of $1 \times 10^4$ cells per well in 96-well plates and incubated at 37°C with indicated antibodies (1 μM) for 24 h or 48 h. Then, cell viability was analyzed using a colorimetric MTT assay (Sigma-Aldrich, TOX1); the absorbance was then measured at 570 nm and read by a microplate reader (Molecular Devices).

**Confocal immunofluorescence microscopy**

Confocal microscopy was performed for detection of internalized VLs and cytotransmabs in cultured cells. Briefly, cells (5 \times 10^8) that were grown on 12-mm diameter coverslips in 24-well culture plates were treated with indicated antibodies, as specified in the Figure Legends. For non-adherent cell lines, cells (2 \times 10^5) were grown on 12-mm diameter coverslips that were pre-coated with poly-L-lysine (Sigma-Aldrich, P8920). After 2× washes with PBS, the cells were washed 2× for 30 s at 25°C with low-pH glycine buffer (200 mM glycine, 150 mM NaCl, pH 2.5), followed by 2 additional washes with PBS to remove non-internalized and nonspecifically surface-bound antibodies. After fixation with 4% paraformaldehyde (PFA) in PBS for 10 min at 25°C, permeabilization with PERM-buffer (0.1% saponin, 0.1% sodium azide, 1% BSA in PBS) for 10 min at 25°C, and then blocking with 2% BSA in PBS for 1 h at 25°C, the internalized cytotransmabs were detected with FITC- or TRITC-conjugated goat anti-human IgG antibodies for 2 h at 25°C. Protein-A-tagged VLs were detected with rabbit IgG and subsequently with TRITC-conjugated goat anti-rabbit antibody. The nucleus was stained with Hoechst 33342 for 5 min in PBS. After mounting the coverslips onto glass slides with Perma Fluor aqueous mounting medium (Thermo Scientific, TA-030-FM), center-focused single z-section images were obtained on a Zeiss LSM710 system with ZEN software (Carl Zeiss). In case of using 63× objective lens in confocal microscope, zoom factor 3 was applied for better resolution.
**Heparin competition assay**

Cells were pretreated with 300 IU/mL heparin (Sigma-Aldrich, H3149) for 30 min at 37°C prior to the addition of cytortransmabs.17

**Experiments with endocytosis markers and inhibitors**

For co-localization with endocytosis markers, cells were co-treated with cytortransmabs (1 μM) and either Alexa Fluor 488-transferrin (TF, 10 μg/mL), FITC-cholera toxin B (Ctx-B, 10 μg/mL), or Oregon green-dextran (10 μg/mL) prior to cell fixation and permeabilization.15 In experimentation with inhibitors for endocytic pathways, cells were pretreated for 30 min at 37°C with CPZ (10 μg/mL), dansylcadaverine (200 μM), MβCD (5 mM), nystatin (50 μg/mL), EIPA (10 μM), wortmannin (200 nM), Cyt-D (1 μg/mL), or dynasore (40 μM) and then incubated with TMAb4 (1 μM) for an additional 2 h.15 Internalized TMAb4 detected TRITC-conjugated anti-Human IgG Fc antibody. The internalization levels of TMAb4 in the presence of inhibitors were represented as percentage (%) by comparing the fluorescence intensity from the inside of cells (n > 100 cells per group) with that of control cells that were not treated with the endocytosis inhibitors.

**Analysis of calcine release from endosomes**

For tracing endosomal release of cytortransmabs using calcine (Sigma-Aldrich, C0875), cells were incubated for 4 h with cytortransmabs (5 μM) in serum-free media at 37°C using adalimumab as a non-internalizing negative control. Subsequently, 50 μM of calcine was added for 2 h at 37°C.55 Cells were then washed 3 times with PBS and fixed. Calcine fluorescence was analyzed by confocal microscopy.

**KT4 and KRS co-localization**

HeLa cells were transfected with plasmids encoding GFP-tagged KRS (generously provided by Dae Gyu Kim, Seoul National University, Seoul, Korea) using Lipofectamine™ 2000 reagent (Invitrogen). After incubation for 24 h, the transfected cells were incubated with TMAb4 or KT4 (20 μM) for 2 h and then analyzed by confocal microscopy.

**Pulse-chase experiment to monitor intracellular trafficking of cytortransmab**

Cells grown on coverslips in 24-well culture plates were incubated with 3 μM of cytortransmab for 30 min, quickly washed 3 times with PBS, and then incubated at 37°C for the indicated periods of time. After washing with PBS, stripping with low pH glycine buffer, fixation, permeabilization, and blocking of the cells, internalized cytortransmabs were stained with FITC- or TRITC-conjugated anti-human antibody, and subcellular organelles were stained with anti-EA1, anti-caveolin-1, anti-calnexin, or anti-58K Golgi protein, followed by the appropriate FITC- or TRITC-conjugated secondary antibodies.17 Lysosomes were visualized with LysoTracker® Red DND-99 that was diluted in medium (1 μM) and directly added to the cell culture for 30 min at 37°C. To visualize clathrin-mediated endosomes, Alexa Fluor 488-transferrin (10 μg/mL) was added to cell culture for 30 min before fixing cells. For the inhibition of proteosomal degradation, a pulse-chase experiment was performed in the presence or absence of MG132 (30 μM).

**Immunoprecipitation and protein gel blotting**

Cells that were grown on 100 mm² plate were incubated with TMAb4 and KT4 for 12 h and then cell lysates were extracted using 20 mM Tris-HCl (pH 7.4) buffer containing 150 mM NaCl, 0.5% Triton X-100, 0.1% SDS, and protease inhibitors (Halt Protease Inhibitor Cocktail, Thermo Scientific, 78440). Subsequently, the cells were incubated with protein A agarose for 2 h at 4°C with agitation.50 After washing 3 times with cold lysis buffer, the precipitates were dissolved in the SDS sample buffer. Western blotting was then performed following the standard procedure, as previously described.59 Proteins were visualized using a PowerOpti-ECL western blotting detection reagent (Animal Genetics) and an ImageQuant LAS 4000 mini (GE Healthcare). Equal amount of lysates were analyzed by protein gel blotting with β-actin as a loading control.

**Statistical analysis**

Data are represented as mean ± SD of at least 3 independent experiments that were performed in triplicate, unless otherwise specified. Comparison between the experimental and control data was analyzed for statistical significance by a 2-tailed unpaired Student’s t-test using Excel (Microsoft). A p value of less than 0.05 was considered statistically significant.

Details regarding the reagents and antibodies, SEC, ELISA, surface plasmon resonance (SPR), DNA hydrolyzing assay, flow cytometry, and live cell imaging are provided in the Supplementary Materials and Methods.

**Disclosure of Potential Conflicts of Interest**

No potential conflicts of interest were disclosed.

**Acknowledgments**

The authors thank Dr. Dae Gyu Kim (Medicinal Bioconvergence Research Center, Gyeonggi, Korea) and Prof. Hyunbo Shim (Ewha Womans University, Korea) for generously providing the plasmid expressing GFP-fused KRS and anti-KRS C12 scFv, respectively.

**Funding**

This work was supported by the Pioneer Research Center Program (2014M3C1A3051470), the Global Frontier Project (2013M3A6A4043874), and the Priority Research Center Program (2012-0006687) through the National Research Foundation of Korea, by the Ministry of Science, ICT & Future Planning.

**Supplemental Material**

Supplemental data for this article can be accessed on the publisher’s website.
References

1. Marshall AL, Frenzel A, Schirrmann T, Schungel M, Dubel S. Targeting antibodies to the cytoplasm. MAbs 2011; 3:3-16; PMID:21099369; http://dx.doi.org/10.4161/mabs.3.1.1141.

2. Marshall A, Zhang C, Frenzel A, Schirrmann T, Huse M, Perez F, Dubel S. Delivery of antibodies to the cytosol: Debunking the myths. MAbs 2014; 6:943-56; PMID:24848507.

3. Ivanova AA, Khuri FR, Fu H. Targeting protein-protein interactions as an anticancer strategy. Trends Pharmacol Sci 2013; 34:393-400; PMID:23725764; http://dx.doi.org/10.1016/j.tips.2013.04.007.

4. Freund G, Sibler AP, Desplançq D, Oulad-Abdelghani M, Vigneron M, Gannot J, Van K, Krissansen GM, Wei S. Engaging endogenous nuclear antigens by electrotransfection of monoclonal antibodies in living cells. MAbs 2013; 5:518-22; PMID:23765067; http://dx.doi.org/10.4161/mabs.25884.

5. Wall CO, Biri S, Adbih A, Erbacher P. A practical approach for intracellular protein delivery. Cytotherapy 2008; 10:46-1; PMID:19002840; http://dx.doi.org/10.1080/14653240802284712.

6. Salomone F, Cardarelli F, Di Luca M, Boccardi C, Orecchia P, et al. Internalization via Antennapedia protein transduction domain of an scFv antibody toward c-Myc protein. FASEB J 2008; 22:1237-45; PMID:18048579; http://dx.doi.org/10.1096/fj.07-8865com.

7. Magdelaine-Beuzelin C, Kaas Q, Wehbi V, Ohresser M, Lejeune MM, Cregier E, et al. Cellular internalization of antibodies: Endocytosis and intracellular trafficking of antibodies in antigen presenting cells. Autoimmun 2006; 26:52-6; PMID:16368224; http://dx.doi.org/10.1158/1535-5384.mab.2005.10.008.

8. Magdelaine-Beuzelin C, Kaas Q, Wehbi V, Ohresser M, Cregier E, et al. Understanding the mechanisms of endocytosis. Annu Rev Biochem 2009; 78:857-90; PMID:19317650; http://dx.doi.org/10.1146/annurev.biochem.78.032507.135050.

9. Ewert S, Huber T, Honegger A, Pluckthun A. Biophysical insights into the mechanism of antibody-promoted cellular internalization. Mol Life Sci 2009; 66:1985-97; PMID:19373434; http://dx.doi.org/10.1007/s11011-008-9179-2.

10. Lee WR, Jang JY, Kim JS, Kwon MH, Kim YS. Gene silencing by cell-penetrating, sequence-selective and nucleic-acid hydrolysing antibodies. Nucleic Acids Res 2010; 38:1536-69; PMID:20070602; http://dx.doi.org/10.1093/nar/gkq1145.

11. Kim A, Shin TH, Shin SM, Pham CD, Choi DK, Kwon MH, Kim YS. Cellular internalization mechanism and intracellular trafficking of filamentous M13 phage displaying recombinant tobacco and TAT peptide. PLoS One 2012; 7:e51813; PMID:23251631; http://dx.doi.org/10.1371/journal.pone.0051813.

12. Kim DS, Lee SH, Kim JS, Lee SC, Kwon MH, Kim YS. Generation of chimeric anti-DNA hydrolysing catalytic antibodies by complementarity determining region grafting. Biochem Biophys Res Commun 2009; 379:314-8; PMID:19105171; http://dx.doi.org/10.1016/j.bbrc.2009.04.104.

13. Whitlegg NR, Rees AR. WAM: an improved algorithm for modelling antibodies on the WEB. Protein Eng 2000; 13:819-24; PMID:11239808; http://dx.doi.org/10.1016/S0954-0039(00)00189-8.

14. Lazarovits NL, Egan RF, Dijkstra I. 3D methodology and intracellular trafficking dynamics in the development of antibody drug conjugates. MAbs 2013; 5:13-21; PMID:23221464; http://dx.doi.org/10.4161/mabs.22854.

15. Dong J, Li J, Zheng J, Tong Y, Kumar R. Mechanisms of endocytosis. Annu Rev Biochem 2009; 78:857-90; PMID:19317650; http://dx.doi.org/10.1146/annurev.biochem.78.032507.135050.

16. Avignolo C, Baguasso L, Biasotti B, Melchiori A, Tanielli M, Bagnasco L, Biasotti B, Melchiori A, et al. Implications of annexin V and MTO1. J Biol Chem 2008; 283:1156-66; PMID:17947238; http://dx.doi.org/10.1074/jbc.M706190200.

17. Lee SH, Park DW, Sung ES, Park HR, Kim JK, Kim YS. Humanization of an agonistic anti-death receptor 4 single chain variable fragment antibody and avidity-mediated enhancement of its cell death-inducing activity. Mol Immunol 2010; 47:816-24; PMID:19864027; http://dx.doi.org/10.1016/j.molimm.2009.09.041.

18. Magdelaine-Beuzelin C, Kaas Q, Wibchi V, Ohresser M, Jefferis R, Lefranc MP, Watier H. Structure-function relationships of the variable domains of monoclonal antibodies approved for cancer treatment. Crit Rev Oncol Hematol 2007; 64:210-25; PMID:17624800; http://dx.doi.org/10.1016/j.critrevonc.2007.01.011.

19. Su H, Liang S, Guo H, Zhang D, Li H, Wang X, Yang W, Qian W, Hou S, Wang H, et al. Comparison of the inhibition mechanisms of adalimumab and infliximab in treating tumor necrosis factor-alpha-associated diseases from a molecular view. J Biol Chem 2013; 288:2705-97; PMID:233943614; http://dx.doi.org/10.1074/jbc.M11249640.

20. Muller YA, Chen Y, Christinger FW, Li B, Cunningham RC, Lowman HB, de Vos AM. VEGF and the Fab fragment of a humanized neutralizing antibody: crystal structure of the complex at 2.4 A resolution and mutational analysis of the interface. Structure 1998; 6:1153-67; PMID:9753694; http://dx.doi.org/10.1016/s0969-2126(98)00116-6.

21. Vargas-Madrazo E, Paz-Garcia E. An improved model of association for VH-VL-immunoglobulin domains: asymmetries between VH and VL in the packing of some immunoglobulin domains. Mol Biol 2003; 252:531-53; PMID:12448801; http://dx.doi.org/10.1002/jmr.613.

22. Ewer S, Huber T, Honegger A, Pluckthun A. Biophysical properties of human antibody variable domains. J Mol Biol 2003; 325:531-53; PMID:12448801; http://dx.doi.org/10.1002/jmr.613.

23. Wei XY, Holliger P, Munzig AR, Williams RL. The 2.0-A resolution crystal structure of a trimeric antibody fragment with noncojugate VH-VL domain pairs shows a rearrangement of VH CDR3. Proc Natl Acad Sci U S A 1997; 94:9637-42; PMID:9275175; http://dx.doi.org/10.1073/pnas.94.18.9637.

24. Rich JP, Melkov K, Brooks P, Prewot B, Lebbe B, Chernomordik LV. Cellular uptake of unconjugated TAT peptide involves clathrin-dependent endocytosis and heparan sulfate receptors. J Biol Chem 2005; 280:15360-6; PMID:15687490; http://dx.doi.org/10.1074/jbc.M410606200.

25. Yu Y, Wang H, Jacobs JD, Yamul RC, Smith DF, Libeer A. Role of cellular heparan sulfate proteoglycans in infection of human adenovirus serotype 5 and 35. PLoS Pathog 2008; 4:e1000189; PMID:18974862; http://dx.doi.org/10.1371/journal.ppat.1000189.

26. Khalil IA, Kogure K, Akita H, Harashima H. Uptake pathways and subsequent intracellular trafficking in nonviral gene delivery. Pharmacol Rev 2006; 58:32-45; PMID:16507881; http://dx.doi.org/10.1123/pr.58.1.8.

27. Murray RC, Wang H, Jacobs JD, Yamul RC, Smith DF, Libeer A. Cell-penetrating, sequence-selective and nuclear-acid hydrolysing antibodies enter cells via caveolar endocytosis and modulate expres-
44. Vendeville A, Rayne F, Bonhoure A, Bertache N, Montecourrier P, Beaumelle B. HIV-1 Tat enters T cells using coated pits before translocating from acidified endosomes and eliciting biological responses. Mol Biol Cell 2004; 15:2347-60; PMID:15020715; http://dx.doi.org/10.1091/mbc.E03-12-0921

45. Ratts R, Zeng H, Berg EA, Blue C, McComb ME, Costello CE, vanderSpek JC, Murphy JR. The cytosolic entry of diphtheria toxin catalytic domain requires a host cell cytosolic translocation factor complex. J Cell Biol 2003; 160:1139-50; PMID:12668662; http://dx.doi.org/10.1083/jcb.200210028

46. Hitz T, Iten R, Gardiner J, Namoto K, Walde P, Seebach D. Interaction of alpha-and beta-oligoarginine-acids and amides with anionic lipid vesicles: a mechanistic and thermodynamic study. Biochemistry 2006; 45:5817-29; PMID:16669625; http://dx.doi.org/10.1021/bi060285d

47. Reiter Y, Schuck P, Boyd LF, Plaksin D. An antibody single-domain phage display library of a native heavy chain variable region: isolation of functional single-domain VH molecules with a unique interface. J Mol Biol 1999; 290:685-98; PMID:10395823; http://dx.doi.org/10.1006/jmbi.1999.2923

48. Tanaka T, Williams RL, Rabbitts TH. Tumour prevention by a single antibody domain targeting the interaction of signal transduction proteins with RAS. EMBO J 2007; 26:5250-9; PMID:17568777; http://dx.doi.org/10.1038/sj.emboj.7601744

49. Zhang H, Yun S, Batuwangala TD, Steward M, Holmes SD, Pan L, Tightiouart M, Shin HJ, Koenig L, Park W, et al. A dual-targeting antibody against EGFR-VEGF for lung and head and neck cancer treatment. Int J Cancer 2012; 131:956-69; PMID:221918971; http://dx.doi.org/10.1002/ijc.26427

50. Shin TH, Sung ES, Kim YJ, Kim KS, Kim SH, Kim SK, Lee YD, Kim YS. Enhancement of the tumor penetration of monoclonal antibody by fusion of a neuropilin-targeting Peptide improves the antitumor efficacy. Mol Cancer Ther 2014; 13:651-61; PMID:24435448; http://dx.doi.org/10.1158/1535-7163.MCT-13-0748

51. Yang HY, Kang KJ, Chung JE, Shin H. Construction of a large synthetic human scFv library with six diversified CDRs and high functional diversity. Mol Cells 2009; 27:225-35; PMID:19277506; http://dx.doi.org/10.1007/s10059-009-0028-9

52. Back DS, Kim YS. Construction of a large synthetic human fab antibody library on yeast cell surface by optimized yeast mating. J Microbiol Biotechnol 2014; 24:608-20; PMID:24394194; http://dx.doi.org/10.4014/jmb.1401.01002
Supplementary Information

A general strategy for generating intact, full-length IgG antibodies that penetrate into the cytosol of living cells

Dong-Ki Choi, Jeomil Bae, Seung-Min Shin, Ju-Yeon Shin, Sunghoon Kim, and Yong-Sung Kim

Inventory of Supplementary Information

Supplementary Figure legends S1 to S8
Supplementary Movie S1
Supplementary Materials and Methods
Supplementary References
Supplementary Figure S1. (A) Amino acid sequence alignment of m3D8, hT0, hT2 and hT3 VL single domain antibodies. CDR residues are indicated by brackets ([ ]). The Vernier zone residues in the β-sheet framework closely underlying CDRs are underlined and bolded. The two Vernier zone residues back mutated in hT2 and hT3 VLs with the corresponding murine residues (I2L and L4M) are indicated by bold, red color. Amino acids changes in Vκ1 framework of hT3 VL from Vκ3 framework of hT2 VL are colored by blue. Residues are numbered according to the Kabat numbering system.1 (B and C) The humanized hT2 and hT3 VLs retained the caveolae-mediated endocytosis pathway of m3D8 VL, determined by co-localization of internalized VLs with endocytosis markers (B) and effects of endocytosis inhibitors on the cellular uptake (C). In (B), HeLa cells were co-treated at 37 °C for 2 h with VLs (10 µM) and endocytosis markers including 10 µg/ml Alexa Fluor 488-transferrin (TF) for clathrin-mediated endocytosis, FITC-cholera toxin B (Ctx-
B) for caveolae-mediated endocytosis, and Oregon green-dextran (Dextran) for macropinocytosis \(^2,^3\) prior to the confocal microscopy analysis. In (C), HeLa cells were pre-treated for 30 min with CPZ (10 µg/ml), MβCD (5 mM) or Cyt-D (1 µg/ml) and then incubated each VL for additional for 2 h, followed by confocal microscopy analysis. In (B and C), internalized Protein-A-tagged VLs were detected with rabbit IgG and subsequent TRITC-conjugated goat anti-rabbit antibody.\(^3\) Images show the merging of markers (green) and/or VLs (red) and Hochest33342-stained nuclei (blue) at the centered single confocal section. Image magnification, 630×; scale bar, 5 µm.
Supplementary Figure S2. Generation of humanized hT4 VL with the highest frequent amino acids at the main VH-interacting positions on the consensus sequence of Vκ1 family germline segments.

(A) Analysis of VH-VL interface of antibodies tested in our study. Left cartoon represents the VH-VL interface based on the three-dimensional structure of adalimumab (PDB 3wd5)⁴, prepared by PyMol software. The right panel shows the 10 positions mostly involved in VH-VL interactions and the frequency of amino acids at each position in percentage (grey boxes), determined by structural analyses of 23 crystallized VH-VL interfaces.⁵ Each position is color-coded based on the observed contact frequency from the analyses of 23 VH-VL interfaces. The interacting residues at the VH-VL interface with contact frequency above 50% and between 20% and 50% are also indicated by red solid lines and black dotted lines, respectively. The amino acids at the 10 positions of VH and VL of antibodies (adalimumab, bevacizumab, TMab3 and TMab4) used in this study are also shown in single letter code. The hT3 VL conserved the highest frequent amino acids at all of the VH-
interacting positions, except for two residues of K89 and S91 in VL-CDR3 that commonly interact with 103-3 and 95 residues in VH-CDR3, respectively. Thus we designed a hT3 variant, dubbed hT4, with two substitutions of K89Q and S91Y to have the most frequently used amino acids of human VLs at the two positions so that hT4 can be broadly associated with various human VH gene family.

(B) Sequence alignment of VLs of hT3, hT4, adalimumab, and bevacizumab. The 10 positions of VL mostly involved in the interactions with VH are indicated by bold, blue color. CDRs indicated by brackets.
Supplementary Figure S3. Biochemical characterizations of the purified parent mAbs and cytotransmabs. (A) Direct ELISA to determine the antigen binding activity of TMab4, HuT4, AvaT4, bevacizumab, and adalimumab antibodies (100 nM) to plate-coated antigen VEGF-A (0.05 µg/ml) or TNFα (0.1 µg/ml). (B) DNA hydrolyzing activity assay of the indicated antibodies by agarose gel electrophoresis. The supercoiled plasmid pUC19 (2.2 nM) was incubated with m3D8 scFv (100 nM, 500 nM) or IgG-format cytotransmabs (TMab4, HuT4, and AvaT4, 100 nM) for 1 h at 37 °C in TBS buffer (pH 7.4) containing 2 mM MgCl₂ (indicated as ‘Mg’) or 50 mM EDTA (indicated as ‘E’). The reaction mixtures were analyzed by 0.7 % agarose gel electrophoresis, and then stained with ethidium bromide (EtBr). The plasmid incubated with the buffer alone and molecular mass markers were labeled as ‘Buffer’ and ‘M’, respectively. The m3D8 scFv was used as a positive control. We previously reported that m3D8 scFv hydrolyzes DNAs in the presence of Mg²⁺, but not EDTA.²,³,⁶
**Supplementary Figure S4.** Cytotransmabs internalizes into various types of live cells with internalizing efficiency of almost 100%. (A) Cellular internalization and localization of cytotransmabs (TMab4, HuT4 and AvaT4) and control mAbs (adalimumab and bevacizumab) in PANC-1, HT-29 and MCF-7 cells, treated with the antibodies (1 μM) for 6 h at 37 °C. Image magnification, 630× (zoom factor 2); scale bar, 5 μm. (B) Internalization efficiency of cytotransmabs (TMab4, HuT4 and AvaT4) observed for numerous cells of HeLa, PANC-1, HT-29 and MCF-7, treated with the antibodies (1 μM) for 6 h at 37 °C. The images are representative of hundreds of cells examined by confocal microscopy. Image magnification, 400× (zoom factor 1); scale bar, 20 μm. In (A and B), after removing cell-surface bound antibodies with low pH glycine buffer (pH 2.5), internalized antibodies were visualized with FITC-conjugated anti-human IgG Fc antibody. Images show the merging of antibodies (green) and Hochest33342-stained nuclei (blue) at
the centered single confocal section. (C) Representative FACS scatter plots of HeLa cells, treated with the indicated antibodies (1 µM) for 6 h at 37 °C prior to FACS analysis, showing the internalization efficiency of cytotransmabs (TMab4 and AvaT4) and the control mAb (Bevacizumab). Internalized antibodies were stained with Alexa Fluor 488-conjugated anti-human IgG antibody. 'Control' means the cells left untreated with antibodies. Gating (rectangles) indicate the cells with Alexa Fluor 488 positive fluorescence compared to the untreated control. The indicated percentages were the frequency of positive cell population entering the boxed gate.
Supplementary Figure S5. Cytotoxicity of internalized cytotoxtransmans in PANC-1 cells, treated with the indicated antibodies (1 μM) at 37 °C for 24 h or 48 h. (A) The morphological features of cells were taken by phase-contrast microscopy after 48 h. Image magnification, 100×; scale bar, 20 μm. (B) The cell viability was determined by MTT assay after 24 h or 48 h. The data represent mean ± SD versus PBS-treated controls.
Supplementary Figure S6. Confocal fluorescence images showing effects of endocytosis inhibitors on TMab4 internalization into HeLa cells, as described in Fig. 3E. HeLa cells were pre-treated for 30 min at 37 °C with CPZ (10 μg/ml), dansylcadaverine (200 μM), MβCD (5 mM), nystatin (50 μg/ml), EIPA (10 μM), wortmannin (200 nM), Cyt-D (1 μg/ml) or dynasore (40 μM) and then incubated with TMab4 for additional 2 h. Internalized TMab4 was stained with TRITC-conjugated anti-human IgG Fc antibody and analyzed by confocal microscopy. Images show the merging of TMab4 (red) and Hoechst33342-stained nuclei (blue) at the centered single confocal section. Scale bar represents 5 μm.
Supplementary Figure S7. Time-lapse live cell imaging to monitor cellular internalization and endosomal release of TMab4. HeLa cells were incubated with Alexa Flour 488-labeled TMab4 (1 μM) and real-time internalization of TMab4 was observed by time-lapse imaging. The dead time between TMab4 treatment and image taking was about 5 min. (A and B) Montage image (A) and quantification of TMab4 internalization and cytosolic accumulation (B), monitored for 2 h with 3 min interval. In (A), representative montage images showing cellular internalization and localization, taken at the indicated times at the centered single confocal section during 2 h TMab4 internalization. Left-top DIC image was added to show cytosolic region and nucleus of cells. Cell boundary was drawn with green line and nucleus was filled with blue color. Image magnification, 630×; scale bar, 10 μm. In (B), measurement of TMab4 fluorescence intensity in the cytosolic regions (n = 13 cells) with the incubation time. Data are presented as mean ± SEM.
**Supplementary Figure S8.** Kinetic parameters for the interactions of C20 and KT4 IgG antibodies with soluble KRS, monitored by SPR. The binding affinity of the anti-KRS antibodies were measured using purified protein by surface resonance plasmon method measured using a BIAcore 2000. (A) SPR sensograms showing the kinetic interactions of C20 and KT4 with surface-immobilized KRS. (B) Kinetic interaction parameters obtained from (A) data using BIAevaluation software. 

The equilibrium dissociation constants ($K_{D1}$) were calculated from the relationship of $K_{D1} = k_d1 / k_a1$ using the bivalent binding model. 

The apparent equilibrium dissociation constants ($K_D$) including the avidity binding were analyzed using the 1:1 Langmuir model. Each value represents the mean ± SD of two independent experiments. In each experiment, at least five data sets were used in the determination of the kinetic constants.

### Table

| IgG clones | $k_a1$ (M$^{-1}$s$^{-1}$) | $k_d1$ (s$^{-1}$) | $k_a2$ (1/RUs) | $k_d2$ (s$^{-1}$) | $K_{D1}$ (M)$^a$ | $K_D$ (M)$^b$ |
|------------|--------------------------|-----------------|---------------|-----------------|-----------------|----------------|
| C20        | (2.89 ± 0.31) × 10$^4$   | (4.77 ± 0.26) × 10$^{-3}$ | (2.54 ± 0.38) × 10$^{-3}$ | (8.88 ± 0.56) × 10$^{-2}$ | (1.65 ± 0.43) × 10$^{-4}$ | (0.58 ± 0.05) × 10$^{-9}$ |
| KT4        | (5.32 ± 1.21) × 10$^4$   | (3.27 ± 1.10) × 10$^{-2}$ | (4.85 ± 0.87) × 10$^{-5}$ | (2.32 ± 0.31) × 10$^{-3}$ | (6.13 ± 0.52) × 10$^{-7}$ | (36.3 ± 4.9) × 10$^{-6}$ |
**Supplementary Movie S1.** Live cell imaging to monitor cellular internalization and endosomal release of Alexa488-labeled TMab4. Movies showing the internalization and endosomal escape of TMab4, tracked for 2 h with 3 min interval. Rapid internalization of TMab4 was indicated by the appearance of small intracellular punctuate structures, the number of which increased with time in the cytoplasmic regions. The cytosolic release of TMab4 was indicated by gradual increase diffuse fluorescence signal intensity in the cytosolic regions.
Supplementary Materials and Methods

Reagents and antibodies

Chlorpromazine (CPZ, C8138), dansylcadaverine (30432), methyl-β-cyclodextrin (MβCD, C4555), nystatin (N6261), 5-(N-Ethyl-N-isopropyl) amiloride (EIPA, A3085), wortmannin (W1628), cytochalasin D (Cyt-D, C8273), dynasore (D7693), MG132 (M7449), rabbit IgG (I5006), FITC-cholera toxin B (Ctx-B, C1655), fluorescein isothiocyanate (FITC) conjugated anti-human IgG (Fc specific, F9512) and tetramethyl-rhodamine isothiocyanate (TRITC) conjugated anti-rabbit IgG (T6778) antibodies were purchased from Sigma-Aldrich. Alexa 488-transferrin (TF, T13342), Oregon green-dextran (D7173), LysoTracker® Red DND-99 (L7528) and were obtained from Invitrogen (Molecular Probes). Horse radish peroxidase (HRP) conjugated anti-mouse IgG (Fc specific, #7076) and anti-p53 (#9282) antibodies were from Cell Signaling. HRP conjugated anti-rabbit IgG (Fc specific, sc-2004), HRP-conjugated anti-goat IgG (Fc specific, sc-2033), anti-β-actin (sc-69879), anti-EEA1 (sc-53939), anti-caveolin-1 (sc-53564), anti-calnexin (sc-70481) and anti-58K Golgi protein (sc-58770) antibodies were purchased from Santa Cruz Biotechnology. Anti-human IgG (Fc specific, 31125) antibody was from Thermo scientific. TRITC-conjugated anti-human IgG (Fc specific, H581) antibody was from Leinco Technologies and anti-KRS mAb was from BIOCON (Medicinal Bioconvergence Research Center, Gyeonggi, Korea). The recombinant proteins, KRS, histidyl-tRNA synthetase (HRS), tryptophanyl-tRNA synthetase (WRS), and ARS-interacting multifunctional protein 1 (AIMP1), and were provided from BIOCON.

Size Exclusion Chromatography (SEC)

SEC analyses were performed on the Agilent 1100 high performance liquid chromatography system using a superdex™200 10/300GC (10 mm × 300 mm, GE Healthcare) size-exclusion column equilibrated with 12 mM sodium phosphate buffer (pH 7.4) containing 500 mM NaCl, 2.7 mM KCl at a flow rate of 0.5 ml/min. Antibodies were analyzed by SEC at a concentration of 200 µg/ml in 70 µl of sample volume. Chromatograms were obtained by monitoring absorbance at 280 nm. The
molecular mass of antibodies was estimated by calculating elution time into the calibration curve, obtained using standard molecular mass marker (alcohol dehydrogenase, 150 KDa; bovine serum albumin, 66 KDa; carbonic anhydrase, 29 KDa) (Sigma-Aldrich).

ELISA
Binding specificity of antibodies to antigens was determined by ELISA. ELISA plates (Nunc, Invitrogen) were coated for 1 h at 4 °C with the indicated antigens (0.05 µg/ml of VEGF, 0.1 µg/ml of TNFα, or 1 µg/ml of KRS, HRS, WRS, or AIMP1) and blocked with 5% (wt/vol) skim milk. After washing with PBST (PBS pH 7.4, 0.01% Tween-20), diluted antibodies in 5% (wt/vol) skim milk were applied to each well for 1 h at 25 °C. After washing with PBST, bound antibodies were detected by labeling with alkaline phosphatase-conjugated goat anti-human IgG (Fc-specific) mAb (Sigma-Aldrich) and then incubating with p-nitrophenylphosphate. Absorbance was read at 405 nm on a VersaMax microplate reader (Molecular devices).

Surface plasmon resonance (SPR)
Kinetic interactions of antibody-protein were measured at 25 °C using Biacore 2000 (GE Healthcare), as previously described.9 After immobilization of KRS protein onto the carboxymethylated dextran surface of a CM5 sensor chip at a level of about 145 response units (RUs), various concentrations of antibodies including C20 (1.25 nM ~ 20 nM) and KT4 (6.25 nM ~ 100 nM) in PBS (pH 7.4) were injected into the flow cell at a flow rate of 30 µl/min for 3 min with 3 min dissociation per cycles. After each cycle, surfaces were regenerated with a buffer (20 mM NaOH, 1 M NaCl, pH 10.0) for 1 min. The binding data were normalized by subtracting the response of a blank cell. Sensogram data were analyzed using BIAevaluation software version 3.1. The kinetic rate constants ($k_a1$, $k_d1$, $k_a2$, and $k_d2$), as well as equilibrium dissociation constant ($K_{D1} = k_d1 / k_a1$)), were estimated by global fitting analysis of the sensograms to the bivalent binding model.10, 11 The apparent equilibrium dissociation constant ($K_D$) including the avidity binding was also calculated using 1:1 Langmuir
DNA hydrolyzing assay

As a substrate, supercoiled plasmid pUC19 were purified using a plasmid miniprep kit (Nanohelix, FPL200). DNA hydrolyzing experiments were initiated by mixing proteins such as m3D8 scFv (0.1 ~ 0.5 µM) and indicated cytotoxicmabs (0.1 µM) with DNA substrates (2.2 nM) in a TBS buffer (50 mM Tris-Cl, pH 7.4, 50 mM NaCl) containing either 2 mM MgCl₂ or 50 mM EDTA, as previously described previously.³, ⁶ Reactions were performed at 37 °C for 1 h and then terminated by incubating with 50 mM EDTA for 10 min at 37 °C. Samples were analyzed on 0.7 % agarose gel electrophoresis.

Live cell imaging

Live-cell time-lapse imaging was performed with Nikon A1 confocal system mounted on eclipse T1 microscope and using a 63× oil objective (NA 1.4). The cell incubation chamber was maintained with humidified atmosphere of 5 % CO₂ and 37 °C. TMab4 labeled with Alexa Fluor 488 antibody labeling kit (Molecular Probes, Invitrogen) were excited at 488 nm and detected with a 500-530 nm band-pass filter, simultaneously acquiring differential-interference-contrast (DIC) images with excitation at 488 nm and detection in the transmission channel. For imaging, laser power was 0.5 % at 488 nm and gain value was 100. To quantify internalized TMab4 in cytosol for time course, cytosolic area of cells was set as region of interest (ROI) and mean fluorescence intensities were measured in all time points using ImageJ software. Fluorescence photobleaching was compensated by measuring the fluorescence of entire image and applying decreased fluorescence ratio. After background correction, all data were plotted using SigmaPlot software.

Flow cytometry

To determine the internalization efficiency of cytotoxicmabs, HeLa cells were incubated with 1 µM of
indicated antibodies for 6 h at 37 °C. After washing the cells with PBS and subsequently with the low pH glycine buffer to remove nonspecifically cell surface-bound antibodies, the cells were trypsinized, fixed, permeabilized, and then blocked prior to the staining of internalized cytostemabs with Alexa Fluor 488-conjugated anti-human IgG antibody. About 1 × 10^4 of cells were analyzed using a FACS Calibur flow cytometer (Becton-Dickinson, Franklin Lakes, NJ), as previously described.  

**Supplementary References**

1. Kabat EA, Wu TT. Identical V region amino acid sequences and segments of sequences in antibodies of different specificities. Relative contributions of VH and VL genes, minigenes, and complementarity-determining regions to binding of antibody-combining sites. J Immunol 1991; 147:1709-19.

2. Jang JY, Jeong JG, Jun HR, Lee SC, Kim JS, Kim YS, et al. A nucleic acid-hydrolyzing antibody penetrates into cells via caveolae-mediated endocytosis, localizes in the cytosol and exhibits cytotoxicity. Cell Mol Life Sci 2009; 66:1985-97.

3. Lee WR, Jang JY, Kim JS, Kwon MH, Kim YS. Gene silencing by cell-penetrating, sequence-selective and nucleic-acid hydrolyzing antibodies. Nucleic Acids Res 2010; 38:1596-609.

4. Hu S, Liang S, Guo H, Zhang D, Li H, Wang X, et al. Comparison of the inhibition mechanisms of adalimumab and infliximab in treating tumor necrosis factor alpha-associated diseases from a molecular view. J Biol Chem 2013; 288:27059-67.

5. Vargas-Madrazo E, Paz-Garcia E. An improved model of association for VH-VL immunoglobulin domains: asymmetries between VH and VL in the packing of some interface residues. J Mol Recognit 2003; 16:113-20.

6. Kim DS, Lee SH, Kim JS, Lee SC, Kwon MH, Kim YS. Generation of humanized anti-DNA hydrolyzing catalytic antibodies by complementarity determining region grafting. Biochem Biophys
7. Kim DG, Lee JY, Kwon NH, Fang P, Zhang Q, Wang J, et al. Chemical inhibition of prometastatic lysyl-tRNA synthetase-laminin receptor interaction. Nat Chem Biol 2014; 10:29-34.

8. Lee SH, Park DW, Sung ES, Park HR, Kim JK, Kim YS. Humanization of an agonistic anti-death receptor 4 single chain variable fragment antibody and avidity-mediated enhancement of its cell death-inducing activity. Mol Immunol 2010; 47:816-24.

9. Shin TH, Sung ES, Kim YJ, Kim KS, Kim SH, Kim SK, et al. Enhancement of the tumor penetration of monoclonal antibody by fusion of a neuropilin-targeting Peptide improves the antitumor efficacy. Mol Cancer Ther 2014; 13:651-61.

10. Lee YH, Iijima M, Kado Y, Mizohata E, Inoue T, Sugiyama A, et al. Construction and characterization of functional anti-epiregulin humanized monoclonal antibodies. Biochem Biophys Res Commun 2013; 441:1011-7.

11. Pericleous LM, Richards J, Epenetos AA, Courtenay-Luck N, Deonarain MP. Characterisation and internalisation of recombinant humanised HMFG-1 antibodies against MUC1. Br J Cancer 2005; 93:1257-66.

12. Troise F, Cafaro V, Giancola C, D'Alessio G, De Lorenzo C. Differential binding of human immunoagents and Herceptin to the ErbB2 receptor. FEBS J 2008; 275:4967-79.

13. Sung ES, Kim A, Park JS, Chung J, Kwon MH, Kim YS. Histone deacetylase inhibitors synergistically potentiate death receptor 4-mediated apoptotic cell death of human T-cell acute lymphoblastic leukemia cells. Apoptosis 2010; 15:1256-69.